                                                                       Federal Register / Vol. 90, No. 74 / Friday, April 18, 2025 / Presidential Documents                      16441

                                                                                                     Presidential Documents



                                                                                                     Executive Order 14273 of April 15, 2025

                                                                                                     Lowering Drug Prices by Once Again Putting Americans First


                                                                                                     By the authority vested in me as President by the Constitution and the
                                                                                                     laws of the United States of America, it is hereby ordered:
                                                                                                     Section 1. Purpose. My first term included numerous significant actions,
                                                                                                     including some of the most aggressive in recent history, to deliver lower
                                                                                                     prescription drug prices to American patients. The message was clear: no
                                                                                                     longer would the executive branch sit idly by as pharmaceutical manufactur-
                                                                                                     ers charged patients in our Nation more than those in other countries for
                                                                                                     the exact same prescription drugs, often made in the exact same places.
                                                                                                     These actions included encouraging the development of generic and bio-
                                                                                                     similar alternatives to higher cost brand name prescription drugs and bio-
                                                                                                     logics to harness competitive forces and increase access to affordable medi-
                                                                                                     cines. The United States also, for the first time, established a pathway
                                                                                                     to expand access to lower cost drugs imported from outside of the country.
                                                                                                     Reform efforts ensured that Government-mandated discounts were passed
                                                                                                     through to patients instead of being retained by middlemen. New price
                                                                                                     transparency rules were promulgated to allow patients, doctors, and employ-
                                                                                                     ers to see the actual cost of prescription drugs before purchase. Insulin
                                                                                                     copayments were capped for Medicare beneficiaries, and manufacturers, in-
                                                                                                     stead of patients and taxpayers, were forced to foot the bill through the
                                                                                                     provision of larger discounts. I also called on the Congress to come to
                                                                                                     the table to help craft sustainable solutions that would promote innovation
                                                                                                     and affordable access for the long-term. When the Congress refused, I pro-
                                                                                                     posed the test of an innovative new payment mechanism that would prevent
                                                                                                     drug manufacturers from charging our patients much higher prices than
                                                                                                     those found abroad.
                                                                                                     Combined, these bold actions were delivering real savings for American
                                                                                                     patients and set the foundation to dramatically narrow the price disparity
                                                                                                     between the United States and foreign nations over time.
                                                                                                     Unsurprisingly, the Biden Administration reversed, walked back, or neglected
                                                                                                     many of these initiatives, undoing the progress made for American patients.
                                                                                                     The Biden Administration then signed into law the misnamed Inflation
                                                                                                     Reduction Act, which included the Medicare Prescription Drug Negotiation
                                                                                                     Program. While this program has the commendable goal of reducing the
                                                                                                     drug prices Medicare and its beneficiaries pay, its administratively complex
                                                                                                     and expensive regime has thus far produced much lower savings than pro-
                                                                                                     jected. Further, accompanying changes to the Medicare Part D program led
                                                                                                     to inflated premiums and diminished coverage choices for seniors, prompting
                                                                                                     a taxpayer-funded bailout of insurance companies offering Part D plans.
                                                                                                     Finally, the program imposes price controls on small molecule prescription
                                                                                                     drugs, usually in tablet or capsule form, 4 years earlier than on large molecule
                                                                                                     biological products. Known as the ‘‘pill penalty,’’ this discrepancy threatens
lotter on DSK11XQN23PROD with FR_PREZDOC2




                                                                                                     to distort innovation by pushing investment towards expensive biological
                                                                                                     products, which are often indicated to treat rarer diseases, and away from
                                                                                                     small molecule prescription drugs, which are generally cheaper and treat
                                                                                                     larger patient populations.
                                                                                                     The American people deserve better. It is time to restore the progress our
                                                                                                     Nation made in my first term to deliver lower prescription drug prices
                                                                                                     by putting Americans first and making America healthy again.


                                            VerDate Sep<11>2014   15:47 Apr 17, 2025   Jkt 265001   PO 00000   Frm 00001   Fmt 4790   Sfmt 4790   E:\FR\FM\18APE2.SGM   18APE2


                                                 16442                 Federal Register / Vol. 90, No. 74 / Friday, April 18, 2025 / Presidential Documents

                                                                                                     Sec. 2. Policy. It is the policy of the United States that Federal health
                                                                                                     care programs, intellectual property protections, and safety regulations are
                                                                                                     optimized to provide access to prescription drugs at lower costs to American
                                                                                                     patients and taxpayers.
                                                                                                     Sec. 3. Improving upon the Inflation Reduction Act. (a) Within 60 days
                                                                                                     of the date of this order, the Secretary of Health and Human Services
                                                                                                     (Secretary), consistent with sections 1191 to 1198 of the Social Security
                                                                                                     Act (42 U.S.C. 1320f–1320f–7) and other applicable law, shall propose and
                                                                                                     seek comment on guidance for the Medicare Drug Price Negotiation Program
                                                                                                     for initial price applicability year 2028 and manufacturer effectuation of
                                                                                                     maximum fair price under such program in 2026, 2027, and 2028. The
                                                                                                     guidance shall improve the transparency of the Medicare Drug Price Negotia-
                                                                                                     tion Program, prioritize the selection of prescription drugs with high costs
                                                                                                     to the Medicare program, and minimize any negative impacts of the maximum
                                                                                                     fair price on pharmaceutical innovation within the United States.
                                                                                                        (b) Within 180 days of the date of this order, the Assistant to the President
                                                                                                     for Domestic Policy, in coordination with the Secretary, the Director of
                                                                                                     the Office of Management and Budget (OMB Director), and the Assistant
                                                                                                     to the President for Economic Policy, shall provide recommendations to
                                                                                                     the President on how best to stabilize and reduce Medicare Part D premiums.
                                                                                                       (c) The Secretary shall work with the Congress to modify the Medicare
                                                                                                     Drug Price Negotiation Program to align the treatment of small molecule
                                                                                                     prescription drugs with that of biological products, ending the distortion
                                                                                                     that undermines relative investment in small molecule prescription drugs,
                                                                                                     coupled with other reforms to prevent any increase in overall costs to
                                                                                                     Medicare and its beneficiaries.
                                                                                                     Sec. 4. Reducing the Prices of High-Cost Drugs for Seniors. Within 1 year
                                                                                                     of the date of this order, the Secretary shall take appropriate steps to develop
                                                                                                     and implement a rulemaking plan and select for testing, consistent with
                                                                                                     42 U.S.C. 1315a(b)(2), a payment model to improve the ability of the Medicare
                                                                                                     program to obtain better value for high-cost prescription drugs and biological
                                                                                                     products covered by Medicare, including those not subject to the Medicare
                                                                                                     Drug Price Negotiation Program.
                                                                                                     Sec. 5. Appropriately Accounting for Acquisition Costs of Drugs in Medicare.
                                                                                                     Within 180 days of the date of this order, as appropriate and consistent
                                                                                                     with applicable law, the Secretary shall publish in the Federal Register
                                                                                                     a plan to conduct a survey under section 1833(t)(14)(D)(ii) of the Social
                                                                                                     Security Act to determine the hospital acquisition cost for covered outpatient
                                                                                                     drugs at hospital outpatient departments. Following the conclusion of this
                                                                                                     survey, the Secretary shall consider and propose any appropriate adjustments
                                                                                                     that would align Medicare payment with the cost of acquisition, consistent
                                                                                                     with the budget neutrality requirement in section 1833(t)(9)(B) of the Social
                                                                                                     Security Act and other legal requirements.
                                                                                                     Sec. 6. Promoting Innovation, Value, and Enhanced Oversight in Medicaid
                                                                                                     Drug Payment. Within 180 days of the date of this order, the OMB Director,
                                                                                                     the Assistant to the President for Domestic Policy, and the Assistant to
                                                                                                     the President for Economic Policy, in coordination with the Secretary, shall
                                                                                                     jointly provide recommendations to the President on how best to ensure
                                                                                                     that manufacturers pay accurate Medicaid drug rebates consistent with sec-
                                                                                                     tion 1927 of the Social Security Act, promote innovation in Medicaid drug
                                                                                                     payment methodologies, link payments for drugs to the value obtained,
                                                                                                     and support States in managing drug spending.
lotter on DSK11XQN23PROD with FR_PREZDOC2




                                                                                                     Sec. 7. Access to Affordable Life-Saving Medications. Within 90 days of
                                                                                                     the date of this order, as appropriate and consistent with applicable law,
                                                                                                     the Secretary shall take action to ensure future grants available under section
                                                                                                     330(e) of the Public Health Service Act, as amended, 42 U.S.C. 254b(e),
                                                                                                     are conditioned upon health centers establishing practices to make insulin
                                                                                                     and injectable epinephrine available at or below the discounted price paid
                                                                                                     by the health center grantee or sub-grantee under the 340B Prescription


                                            VerDate Sep<11>2014   15:47 Apr 17, 2025   Jkt 265001   PO 00000   Frm 00002   Fmt 4790   Sfmt 4790   E:\FR\FM\18APE2.SGM   18APE2


                                                                       Federal Register / Vol. 90, No. 74 / Friday, April 18, 2025 / Presidential Documents                      16443

                                                                                                     Drug Program (plus a minimal administration fee) to individuals with low
                                                                                                     incomes, as determined by the Secretary, who:
                                                                                                       (a) have a high cost-sharing requirement for either insulin or injectable
                                                                                                     epinephrine;
                                                                                                        (b) have a high unmet deductible; or
                                                                                                        (c) have no healthcare insurance.
                                                                                                     Sec. 8. Reevaluating the Role of Middlemen. Within 90 days of the date
                                                                                                     of this order, the Assistant to the President for Domestic Policy, in coordina-
                                                                                                     tion with the Secretary, the OMB Director, and the Assistant to the President
                                                                                                     for Economic Policy, shall provide recommendations to the President on
                                                                                                     how best to promote a more competitive, efficient, transparent, and resilient
                                                                                                     pharmaceutical value chain that delivers lower drug prices for Americans.
                                                                                                     Sec. 9. Accelerating Competition for High-Cost Prescription Drugs. Within
                                                                                                     180 days of the date of this order, the Secretary, through the Commissioner
                                                                                                     of Food and Drugs, shall issue a report providing administrative and legisla-
                                                                                                     tive recommendations to:
                                                                                                        (a) accelerate approval of generics, biosimilars, combination products, and
                                                                                                     second-in-class brand name medications; and
                                                                                                        (b) improve the process through which prescription drugs can be reclassi-
                                                                                                     fied as over-the-counter medications, including recommendations to opti-
                                                                                                     mally identify prescription drugs that can be safely provided to patients
                                                                                                     over the counter.
                                                                                                     Sec. 10. Increasing Prescription Drug Importation to Lower Prices. Within
                                                                                                     90 days of the date of this order, the Secretary, through the Commissioner
                                                                                                     of Food and Drugs, shall take steps to streamline and improve the Importation
                                                                                                     Program under section 804 of the Federal Food, Drug, and Cosmetic Act
                                                                                                     to make it easier for States to obtain approval without sacrificing safety
                                                                                                     or quality.
                                                                                                     Sec. 11. Reducing Costly Care for Seniors. Within 180 days of the date
                                                                                                     of this order, the Secretary shall evaluate and, if appropriate and consistent
                                                                                                     with applicable law, propose regulations to ensure that payment within
                                                                                                     the Medicare program is not encouraging a shift in drug administration
                                                                                                     volume away from less costly physician office settings to more expensive
                                                                                                     hospital outpatient departments.
                                                                                                     Sec. 12. Improving Transparency into Pharmacy Benefit Manager Fee Disclo-
                                                                                                     sure. Within 180 days of the date of this order, the Secretary of Labor
                                                                                                     shall propose regulations pursuant to section 408(b)(2)(B) of the Employee
                                                                                                     Retirement Income Security Act of 1974 to improve employer health plan
                                                                                                     fiduciary transparency into the direct and indirect compensation received
                                                                                                     by pharmacy benefit managers.
                                                                                                     Sec. 13. Combating Anti-Competitive Behavior by Prescription Drug Manufac-
                                                                                                     turers. Within 180 days of the date of this order, the Secretary or his
                                                                                                     designee shall conduct joint public listening sessions with the appropriate
                                                                                                     personnel from the Department of Justice, the Department of Commerce,
                                                                                                     and the Federal Trade Commission and issue a report with recommendations
                                                                                                     to reduce anti-competitive behavior from pharmaceutical manufacturers.
                                                                                                     Sec. 14. General Provisions. (a) Nothing in this order shall be construed
                                                                                                     to impair or otherwise affect:
                                                                                                       (i) the authority granted by law to an executive department or agency,
                                                                                                       or the head thereof; or
lotter on DSK11XQN23PROD with FR_PREZDOC2




                                                                                                       (ii) the functions of the Director of the Office of Management and Budget
                                                                                                       relating to budgetary, administrative, or legislative proposals.
                                                                                                       (b) This order shall be implemented consistent with applicable law and
                                                                                                     subject to the availability of appropriations.
                                                                                                       (c) This order is not intended to, and does not, create any right or benefit,
                                                                                                     substantive or procedural, enforceable at law or in equity by any party


                                            VerDate Sep<11>2014   15:47 Apr 17, 2025   Jkt 265001   PO 00000   Frm 00003   Fmt 4790   Sfmt 4790   E:\FR\FM\18APE2.SGM   18APE2


                                                 16444                 Federal Register / Vol. 90, No. 74 / Friday, April 18, 2025 / Presidential Documents

                                                                                                     against the United States, its departments, agencies, or entities, its officers,
                                                                                                     employees, or agents, or any other person.




                                                                                                     THE WHITE HOUSE,
                                                                                                     April 15, 2025.


                                                 [FR Doc. 2025–06837
                                                 Filed 4–17–25; 8:45 am]
                                                 Billing code 3395–F4–P
lotter on DSK11XQN23PROD with FR_PREZDOC2




                                                                                                                                                                                        Trump.EPS</GPH>




                                            VerDate Sep<11>2014   15:47 Apr 17, 2025   Jkt 265001   PO 00000   Frm 00004   Fmt 4790   Sfmt 4790   E:\FR\FM\18APE2.SGM   18APE2
